McIlrath & Eck LLC Reduces Holdings in Merck & Co., Inc. $MRK

McIlrath & Eck LLC lowered its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 64.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,198 shares of the company’s stock after selling 3,994 shares during the period. McIlrath & Eck LLC’s holdings in Merck & Co., Inc. were worth $264,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Brighton Jones LLC lifted its position in shares of Merck & Co., Inc. by 29.5% in the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock valued at $3,808,000 after acquiring an additional 8,710 shares in the last quarter. Sivia Capital Partners LLC boosted its stake in shares of Merck & Co., Inc. by 52.2% during the second quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock valued at $910,000 after acquiring an additional 3,941 shares during the last quarter. Diversify Advisory Services LLC boosted its stake in shares of Merck & Co., Inc. by 94.1% during the second quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock valued at $2,590,000 after acquiring an additional 15,636 shares during the last quarter. Diversify Wealth Management LLC increased its position in Merck & Co., Inc. by 22.2% during the 2nd quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock worth $3,054,000 after purchasing an additional 6,897 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Merck & Co., Inc. by 111.7% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock worth $53,918,000 after purchasing an additional 359,356 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck’s launch of subcutaneous Keytruda, known as Qlex, and other lifecycle extensions could preserve the drug’s commercial momentum and support exclusivity through 2039. Recent regulatory approvals, pipeline progress and the acquisitions of Terns and Cidara also broaden the company’s oncology and virology prospects. Merck: Heading Into Q2 Earnings, The Keytruda Cliff Looks Increasingly Less Steep
• Positive Sentiment: Analyst estimates have improved, including Erste Group’s modest increase in its FY2027 EPS forecast to $9.54 from $9.52. Barclays has also forecast strong potential appreciation for MRK, reinforcing the constructive sentiment around the shares. Barclays Forecasts Strong Price Appreciation for Merck & Co., Inc. Stock
• Positive Sentiment: Merck declared a quarterly dividend of $0.85 per share, payable October 7 to shareholders of record September 15. The dividend provides ongoing income support, with a reported annualized yield of about 2.6%.
• Neutral Sentiment: MRK is scheduled to release second-quarter 2026 results before the market opens on August 4. Consensus calls for approximately $16.33 billion in sales and a loss of $0.26 per share, with acquisition costs likely affecting reported earnings. Investors will watch Keytruda demand, Gardasil performance and management’s outlook. Should You Buy, Sell or Hold Merck Stock Ahead of Q2 Earnings?
• Neutral Sentiment: Merck and Wellcome’s Hilleman Laboratories are preparing an experimental Ebola vaccine for clinical trials. The initiative supports Merck’s public-health profile but is unlikely to materially affect near-term financial results. Merck, Wellcome Partner With Global Health Group to Make Ebola Vaccine for Clinical Trials
• Negative Sentiment: After a roughly 17% rally since its latest quarterly results, MRK may already reflect much of the favorable Keytruda and pipeline news. Analysts characterize its longer-term valuation as justified rather than clearly inexpensive, while Gardasil weakness and the approaching earnings event remain risks. Merck Stock Looks Cheap on Cash Flow but Fair on Earnings

Merck & Co., Inc. Stock Performance

Merck & Co., Inc. stock opened at $130.49 on Friday. The stock has a fifty day moving average price of $123.17 and a 200 day moving average price of $118.46. Merck & Co., Inc. has a 52 week low of $77.53 and a 52 week high of $135.05. The firm has a market capitalization of $322.28 billion, a P/E ratio of 36.76, a PEG ratio of 5.15 and a beta of 0.19. The company has a current ratio of 1.30, a quick ratio of 1.06 and a debt-to-equity ratio of 1.02.

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.47) by $0.19. The firm had revenue of $16.29 billion for the quarter, compared to analyst estimates of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm’s quarterly revenue was up 4.9% on a year-over-year basis. During the same period last year, the company earned $2.22 EPS. Equities research analysts anticipate that Merck & Co., Inc. will post 2.74 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 7th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.85 per share. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.6%. Merck & Co., Inc.’s dividend payout ratio is currently 95.77%.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on MRK. CICC Research initiated coverage on shares of Merck & Co., Inc. in a research note on Wednesday, June 24th. They issued an “outperform” rating and a $138.00 target price for the company. Weiss Ratings cut shares of Merck & Co., Inc. from a “hold (c+)” rating to a “hold (c)” rating in a research note on Friday, May 15th. Guggenheim lifted their price target on shares of Merck & Co., Inc. from $140.00 to $145.00 and gave the stock a “buy” rating in a report on Monday, July 13th. Cantor Fitzgerald reissued a “neutral” rating and issued a $120.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Finally, Royal Bank Of Canada reissued an “outperform” rating and set a $142.00 price objective on shares of Merck & Co., Inc. in a research note on Wednesday, July 8th. Thirteen investment analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Merck & Co., Inc. presently has an average rating of “Moderate Buy” and a consensus target price of $134.50.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.